Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates[...]
New data from TAR 200 Phase 2b SunRISe 1 study show 84 percent complete[...]
08/02/2024 | Press release | Distributed by Public on 08/02/2024 10:36
Please select the service you want to use:
Smartlinks | Velocity Financial Inc. | Company News | Top Company News | Shareholder Meeting | Financial Services | Investment Funds | Lifestyle and Leisure | Leisure | Securities Issuers | Consumer Lending Companies | New York Stock Exchange (NYSE) | NYSE American | NYSE ARCA Equities | Cboe BZX Exchange | Cboe BYX Exchange | Cboe EDGA Exchange | Cboe EDGX Exchange | NYSE National | FINRA Alternative Display Facility (ADF) | Investors Exchange (IEX) | Nasdaq BX | Nasdaq Intermarket | Nasdaq PSX | NYSE Chicago
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact